Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?

Despite advances in insulin therapies, patients with type 1 diabetes (T1DM) have a shorter life span due to hyperglycaemia-induced vascular disease and hypoglycaemic complications secondary to insulin therapy. Restricting therapy for T1DM to insulin replacement is perhaps an over-simplistic approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Warnes, Harriet, Helliwell, Rebecca, Pearson, Sam Matthew, Ajjan, Ramzi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167310/
https://www.ncbi.nlm.nih.gov/pubmed/30209797
http://dx.doi.org/10.1007/s13300-018-0496-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167310/
https://www.ncbi.nlm.nih.gov/pubmed/30209797
http://dx.doi.org/10.1007/s13300-018-0496-z

Ejemplares similares